Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon Feb 16, 2013 7:08am
270 Views
Post# 20999393

RE: RE: RE: RE: RE: Long weekend ahead

RE: RE: RE: RE: RE: Long weekend ahead

 We moved from sub $2 SP up to peak of $3.3 SP just off of speculation w/o any news. With official licensing deal, I see us easily hitting $5. Other posters have commented that once this stock his $5, that institutional investors will soak up this stock. So 1st licensing deal may be catalyst to get us to $5, followed by institutional investing maintaining if not further boosting the SP. The timing is key. If licensing deal was announced next week, there is still a long gap of time between then and the ASSURE announcement. This lull period could result in depressed SP during this time, but I'm sure our new base would easily maintain at least $4 until the big announcement. 

Bullboard Posts